3M, trading at $0.73 on the NASDAQ. This SniperIQ fundamentals page covers TELA Bio's valuation, profitability (net margin -49.3%), revenue ($80M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
3M
Net Margin-49.3%
Revenue (FY25)$80M

Full research coverage

Frequently Asked Questions

What is TELA Bio's market cap?

TELA Bio (TELA) has a market capitalization of approximately

3M, trading at $0.73 on the NASDAQ. Market cap moves with the live share price.

How profitable is TELA Bio?

TELA Bio runs a net profit margin of -49.3%, a gross margin of 67.3%, and an operating margin of -41.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does TELA Bio generate?

TELA Bio reported revenue of $80M for fiscal year 2025, with net income of -

9M and earnings per share (EPS) of -0.83. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does TELA Bio pay a dividend?

TELA Bio does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is TELA Bio financially healthy?

TELA Bio carries a debt-to-equity ratio of -10.84x and a current ratio of 3.61x, with a market beta of 1.34. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is TELA Bio a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For TELA Bio (TELA) the key facts are: market cap

3M, revenue $80M, 52-week range 0.501-2.14. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track TELA Bio's full fundamentals live

Get TELA Bio's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.